All In Biotech

Drug Trial Radar · NCT06999551

Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.

Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in the Treatment of Diabetes Type 2, in Tunisian Patients.

Last checked: Nov 20, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 1, 2025

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
May 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will have a single arm: the patient on NPH will continue his treatment for 4 weeks, at the end of the NPH treatment, the patient will receive his CGM device for three days for glycemic holter, a switch to insulin glargine is started for a period of 12 weeks with a dose adjustment and a control of the glycemic balance by CGM for three days at the end of the study. The NPH insulin vial is a 10 ml vial dosed at 100 IU/mL, The Glargen vial is in the form of a solution for injection, a 3 ml vial dosed at 100 IU/mL

Conditions

  • Diabetes Mellitus

Interventions

  • switch NPH to glarginDrug

    Switch of patients with type 2 diabetes mellitus from NPH insulin to insulin glargine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. glycaemic variability on insulin glargine (after 12 weeks of use) versus NPH insulin (baseline)Time frame: 4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hedi Chaker Hospital

    Sfax, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.